This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method for altering insulin secretion comprising, contacting a pancreatic islet cell expressing SGK1 with a substance that modulates SGK1.

2. (Original) A method according to claim 1, wherein the expressed SGK1 comprises a selected SNP variant.

3. (Previously presented) A method of claim 1, wherein the modulator of SGK1 is an inhibitor.

4. (Previously presented) A method of claim1, wherein the modulator is an activator of SGK1.

5. (Original) A method of claim 1, wherein the inhibition of SGK1 comprises reversal of the depolarizing effect of glucose, activation of voltage gated Ca-channels and insulin release.

6. (Original) A method according to claim 5, wherein the polymorph SGK1 SNP variant is diagnosed before inhibition.

7. (Currently amended) A method according to claim 1, ~~characterized by the up-regulation of~~ insulin secretion is up regulated.

8. (Previously presented) The method of claim 1 wherein the treated subject suffers from symptoms of diabetes mellitus type-2.

9. (Withdrawn) A method for reducing glucocorticoid induced diabetes mellitus type-2 in a subject in need of such a treatment by modulating the activity of SGK1 in pancreatic islet cells.

10. (Previously presented) The method of claim 1, wherein the treated subject has stress induced hyperglycemia.

11. (Previously presented) The method of claim1, wherein the treated subject has hypoglycemia .

12. (Withdrawn -Currently amended) A method for determining the progression, regression or onset of a disease ~~by measuring the expression of SGK1,~~ comprising taking a sample from the diseased individual and measuring the expression of SGK1.

13. (Withdrawn) A method according to claim 12, wherein the SGK1 comprises s a selected SNP variant.

14. (Withdrawn) A Pharmaceutical composition comprising an SGK1 inhibiting agent together with a pharmaceutically effective carrier, excipient or diluent.

15. (Withdrawn-currently amended) ~~Use of SGK1 inhibitors selected from the listed compounds having the general formula I or II~~ A method for the manufacture of a medicament for the ~~manufacture of a medicamnet~~ treatment of disorders caused by impaired insulin secretion comprising admixing an ~~of~~ SGK1 inhibitor ~~selected from the listed compounds having the general formula I or II~~ of claim 16 together with a pharmaceutically acceptable carrier.

16. (New)
A method for the treatment of disorders caused by impaired insulin secretion comprising administering to a subject in need thereof a ccompound of Formula I



Formula I

wherein
R^1, R^5 is either H, OH, OA, OAc or Methyl,

R^2, R^3, R^4, R^6, R^7, R^8, R^9 or R^{10} is H, OH, OA, OAc, OCF_3, Hal, NO_2, CF_3, A, CN, OSO_2CH_3, SO_2CH_3, NH_2 or COOH,

R^{11} is H or CH_3,

A is C_{1-4} Alkyl,

X is CH_2, CH_2CH_2, OCH_2 or -CH(OH)-,

Hal is F, Cl, Br or I

and

a derivative, salt, solution, isomer or mixture thereof.

17. (New)A method according to claim 16, wherein said compound is:
(3-Hydroxy-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Hydroxy-phenyl)-acidic acid-[1-(4-hydroxy-2-methoxy-phenyl)-ethyliden]-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
Phenylacidic acid-(3-fluor-4-hydroxy-benzyliden)-hydrazid,
(4-Hydroxy-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3,4-Dichlor-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,

m-Tolyl-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
o-Tolyl-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(2-Chlor-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Chlor-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(4-Fluor-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(2-Chlor-4-fluor-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Fluor-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(4-hydroxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(4-hydroxy-2,6-dimethyl-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(3-fluor-4-hydroxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-[1-(4-hydroxy-2-methoxy-phenyl)-ethyliden]-hydrazid,
(3-Methylsulfonyloxy-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3,5-Dihydroxy-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Fluor-phenyl)-acidic acid-(3-fluor-4-hydroxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(4-acetoxy-2-methoxy-benzyliden)-hydrazid,
(3-Trifluormethyl-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
3-(3-Methoxy-phenyl)-propionsaure-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(2,4-dihydroxy-benzyliden)-hydrazid,
(3-Methoxy-phenoxy)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Nitro-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(5-chlor-2-hydroxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(2-hydroxy-5-nitro-benzyliden)-hydrazid,
2-Hydroxy-2-phenyl-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-(2-ethoxy-4-hydroxy-benzyliden)-hydrazid,
(3-Brom-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Methoxy-phenyl)-acidic acid-[1-(4-hydroxy-phenyl)-ethyliden]-hydrazid,
(3,5-Difluor-phenyl)-acidic acid-(4-hydroxy-2-methoxy-benzyliden)-hydrazid,
(3-Hydroxy-phenyl)-acidic acid-(4-hydroxy-2-methyl-benzyliden)-hydrazid,
(3-Hydroxy-phenyl)-acidic acid-(2-ethoxy-4-hydroxy-benzyliden)-hydrazid,

(3-Hydroxy-phenyl)-acidic acid-(2-methoxy-4-hydroxy-6-methyl-benzyliden)-hydrazid,
or
(2-Fluor-phenyl)-acidic acid-(2-methoxy-4-hydroxy-benzyliden)-hydrazid.

18. A method for the treatment of disorders caused by impaired insulin secretion comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula II

II



wherein R^1, R^2, R^3, R^4, or R^5 is
H, A, OH, OA, Alkenyl, Alkinyl, NO_2, NH_2, NHA, NA_2, Hal, CN, COOH, COOA, -OHet, -O-Alkylen-Het, -O-Alkylen-NR^8, R^9 or $CONR^8R^9$,
two groups selected from R^1, R^2, R^3, R^4, or R^5 or -O-CH--CH_2-, -O--CH_2-O-- or -O-CH_2-CH_2-O-,

R^6, R^7 is H, A, Hal, OH, OA or CN,

R^8, R^9 is H or A,

Het is a saturated or unsaturated heterocycle with 1 to 4 N-, O- and/or S-atoms, substituted by one or several Hal, A, OA, COOA, CN or Carbonyloxigen (=O),

A is C_{1-10} Alkyl, wherein 1-7H-atoms may be replaced by F and/or Chlorine,

X, X' is NH or is missing

Hal is F, Cl, Br or I

and

a derivative, salt, solution, isomer or mixture thereof.

19. (New) A method according to claim 18, wherein said compound is:

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2-- fluor-5-trifluormethyl-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(4-chlor-5-trifluormethyl-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2,4-difluor-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2,6-difluor-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(3-fluor-5-trifluormethyl-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(4-fluor-5-trifluormethyl-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(4-methyl-5 -trifluormethyl-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2,3,4,5,6-pentafluor-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2,4-dibrom-6-fluor-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2-fluor-6-trifluormethyl-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2-fluor-5-methyl-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2,3,4-trifluor-phenyl)-urea,

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(4-brom-2,6- difluor-phenyl)-urea

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-(2-fluor-3-trifluormethyl-phenyl)-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[2-(1-tert -butyloxycarbonyl-piperidin-4-yl)-phenyl]-urea,
N-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-2,4-dichlor-benzamid,
N-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-4-chlor-5-tri-fluormethyl-benzamid,
N-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-2-fluor-5-tri-fluormethyl-benzamid,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[3-chlor-5-trifluormethyl-2-(piperidin-4-yloxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[(2-fluor-5-(2-dimethylamino-ethoxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[5-fluor-2-(piperidin-4-yloxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[4-chlor-5-trifluormethyl-2-(piperidin-4-yloxy)-phenyl]-urea, 1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[2-(piperid- in-4-yloxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[2-fluor-5-(2-diethylamino-ethoxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[2-fluor-5-[2-(piperidin-1-yl)-ethoxy]-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[4-fluor-2-(2-dimethylamino-ethoxy)-phenyl]-urea,
[1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[4-fluor-2-(2-diethylamino-ethoxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[3-chlor-4-[2-(morpholin-4-yl)-ethoxy]-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[4-fluor-2-[2-(morpholin-4-yl)-ethoxy]-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[3-chlor-4-(2-dimethylamino-ethoxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[3-chlor-4-(2-diethylamino-ethoxy)-phenyl]-urea,
1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[4-chlor-2-(2-dimethylamino-ethoxy)-phenyl]-urea,

or

1-[4-(4-Amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-phenyl]-3-[2-chlor-5-(2-diethylamino-ethoxy)-phenyl]-urea.